TNF-α evaluation in tonsil cancer

Romanian Journal of Morphology and Embryology

Volumn 56, Issue 1, 2015, Pages 101-106

  Turculeanu, Adriana ^a   Mogoantă, Carmen Aurelia ^a   Ioniţă, Elena ^a   Avrămescu, Carmen Silvia ^a   Afrem, Mihai Cătălin ^a   Costache, Adrian ^b  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Macrophages; Mast cells; TNF ; Tonsil cancer; Tumorigenesis

Indexed keywords

TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; MACROPHAGE; MALE; MAST CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; PHARYNX; SQUAMOUS CELL CARCINOMA; TONSIL TUMOR; TONSILLITIS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; MACROPHAGES; MALE; MAST CELLS; MIDDLE AGED; PHARYNX; TONSILLAR NEOPLASMS; TONSILLITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925304742     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. [1] Trandafir D, Trandafir V, Gogălniceanu D. Strategii actuale în tratamentul cancerului orofaringian. Jurnalul de Chirurgie, Iaşi, 2010, 6(1):10–22.
2. [2] Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol, 2004, 31(6):744–754.
3. [3] Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer, 2002, 38(1):99–166.
4. [4] Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2):74–108.
5. [5] Pindborg JJ, Zheng KH, Kong CR, Lin FX. Pilot survey of oral mucosa in areca (betel) nut chewers on Hainan Island of the People’s Republic of China. Community Dent Oral Epidemiol, 1984, 12(3):195–196.
6. [6] Licitra L, Bernier J, Grandi C, Merlano M, Bruzzi P, Lefebvre JL. Cancer of the oropharynx. Crit Rev Oncol Hematol, 2002, 41(1):107–122.
7. [7] Bailey BJ, Johnson JT, Newlands SD, Calhoun KH, Deskin RW. Head and neck surgery: otolaryngology. Lippincott Williams & Wilkins, Philadelphia, 2006, 1120–1128.
8. [8] Marklund L, Hammarstedt L. Impact of HPV in oropharyngeal cancer. J Oncol, 2011, 2011:509036.
9. [9] Cohan DM, Popat S, Kaplan SE, Rigual N, Loree T, Hicks WL Jr. Oropharyngeal cancer: current understanding and management. Curr Opin Otolaryngol Head Neck Surg, 2009, 17(2): 88–94.
10. [10] Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ. Changing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control, 2000, 11(6):489–495.
11. [11] Mogoantă CA, Ion DA, Budu V, Muţiu G, Salplahta D, Afrem E. Evaluation of microvascular density in inflammatory lesions and carcinoma of palatine tonsil. Rom J Morphol Embryol, 2013, 54(1):179–185.
12. [12] Olaleye O, Moorthy R, Lyne O, Black M, Mitchell D, Wiseberg J. A 20-year retrospective study of tonsil cancer incidence and survival trends in South East England: 1987–2006. Clin Otolaryngol, 2011, 36(4):325–335.
13. [13] Lee SY, Park SY, Kim SH, Choi EC. Expression of matrix metalloproteinases and their inhibitors in squamous cell carcinoma of the tonsil and their clinical significance. Clin Exp Otorhinolaryngol, 2011, 4(2):88–94.
14. [14] Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle, 2009, 8(20):3267–3273.
15. [15] Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol, 2006, 72(11):1605–1621.
16. [16] Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci, 2008, 13:5094–5107.
17. [17] Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factoralpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol, 2004, 4(4):314–320.
18. [18] Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res, 2006, 4(4):221–233.
19. [19] Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res, 2014, 2014:149-185.
20. [20] Atsumi T, Singh R, Sabharwal L, Bando H, Meng J, Arima Y, Yamada M, Harada M, Jiang JJ, Kamimura D, Ogura H, Hirano T, Murakami M. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res, 2014, 74(1):8–14.
21. [21] Rosin MR, Anwar WA, Ward AJ. Inflammation, chromosomal instability, and cancer: the schistosomiasis model. Cancer Res, 1994, 54(7 Suppl):1929s–1933s.
22. [22] Macarthur M, Hold GL, El-Omar EM. Inflammation and cancer. II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol, 2004, 286(4):G515–G520.
23. [23] Dalianis T. Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy (Review). Int J Oncol, 2014, 44(6):1799–1805.
24. [24] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255):539–545.
25. [25] Cordon-Cardo C, Prives C. At the crossroads of inflammation and tumorigenesis. J Exp Med, 1999, 190(10):1367–1370.
26. [26] Itzkowitz SH, Yio X. Inflammation and cancer. IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol, 2004, 287(1):G7–G17.
27. [27] Nathan C. Points of control in inflammation. Nature, 2002, 420(6917):846–852.
28. [28] Coussens LM, Werb Z. Inflammation and cancer. Nature, 2002, 420(6917):860–867.
29. Fulton AM, Loveless SE, Heppner GH. Mutagenic activity of tumor-associated macrophages in Salmonella typhimurium strains TA98 and TA100. Cancer Res, 1984, 44(10):4308–4311.
30. [30] Maeda H, Akaike H. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc), 1998, 63(7):854–865.
31. [31] Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer, 2004, 4(1):71–78.
32. [32] Yan B, Wang H, Rabbani ZN, Zhao Y, Li W, Yuan Y, Li F, Dewhirst MW, Li CY. Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res, 2006, 66(24):11565–11570.
33. [33] Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell, 2004, 6(3):297–305.
34. [34] Slootweg PJ, Eveson JW. Tumours of the oral cavity and oropharynx: introduction. In: Barnes L, Eveson JW, Reichart P, Sidransky D (eds). Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours, IARC Press, Lyon, 2005.
35. [35] Lee DJ, Kwon MJ, Nam ES, Kwon JH, Kim JH, Rho YS, Shin HS, Cho SJ. Histopathologic predictors of lymph node metastasis and prognosis in tonsillar squamous cell carcinoma. Korean J Pathol, 2013, 47(3):203–210.
36. [36] Chen WC, Tsai MH, Wan L, Chen WC, Tsai CH, Tsai FJ. CYP17 and tumor necrosis factor-alpha gene polymorphisms are associated with risk of oral cancer in Chinese patients in Taiwan. Acta Otolaryngol, 2005, 125(1):96–99.
37. [37] Gupta R, Sharma SC, Das SN. Association of TNF-alpha and TNFR1 promoters and 3’ UTR region of TNFR2 gene polymorphisms with genetic susceptibility to tobacco-related oral carcinoma in Asian Indians. Oral Oncol, 2008, 44(5):455–463.
38. [38] Yang CM, Hou YY, Chiu YT, Chen HC, Chu ST, Chi CC, Hsiao M, Lee CY, Hsieh CJ, Lin YC, Hsieh YD, Ger LP. Interaction between tumour necrosis factor-α gene polymorphisms and substance use on risk of betel quid-related oral and pharyngeal squamous cell carcinoma in Taiwan. Arch Oral Biol, 2011, 56(10):1162–1169.
39. [39] Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med, 2001, 193(6):F23–F26.
40. [40] Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer, 2004, 90(11):2053–2058.